ABSTRACT
AIM:To evaluate the mineralocorticoid receptor ( MR) gene - 2G/ C single nucleotide polymorphism in central serous chorioretinopathy ( CSCR ), polymorphism and plasma cortisol level relationship. METHODS: Sixty CSCR patients and 50 controls were included in the study. Inclusion criteria for patients were acute manifestation of CSCR characterized by serous retinal detachment, RPE detachment or dysfunction without evidence of any other possible cause of fluid exudation, such as choroidal neovascularization, inflammation or infiltration. Peripheric blood sample was collected from the participants between 8 and 10 a. m. to avoid the diurnal changes of cortisol levels. MR (NR3C2) gene polymorphism ( rs2070951 ) and plasma cortisol levels sere studied. RESULTS: The genotype frequencies in CSCR group were G/ C (46. 6% ), G/ G (26. 7%) and C/ C (26. 7%). There was no statistically significant difference in terms of genotype distribution among groups ( P = 0. 96 ). The plasma cortisol levels were also studied and the results were 401. 2±162. 1 nmol/ L in the CSCR group and 296. 8±130. 1 nmol/ L in the control group and the difference was statistically significant ( P CONCLUSION: The MR (NR3C2) gene polymorphism is not associated with CSCR and the plasma cortisol levels.
ABSTRACT
OBJECTIVE: This study evaluated the effects of sibutramine on intraocular pressure (IOP) and body-mass index (BMI). METHODS: Thirty obese females (body-mass index>30 kg/m2) treated with sibustramine (10 mg/day) plus plus diet restriction for 3 months were included in the study. IOP, BMI, and blood biochemical parameters were measured at the beginning and end of the treatment. Results were evaluated statistically by paired t-test, analysis of variance, and least-significant difference test. RESULTS: A statistically significant decrease was observed in the mean body-mas index (p<0.001) ans serum triglyceride (p<0.001), while a statistically significant increase was observed in IOP (p=0.54). CONCLUSION: While sibustramine provided an effective means for weight loss, it caused a slight increase in IOP, although this was not statistically significant. Nevertheless, it is prudent to monitor IOP in selected obese patients treated with sibustramine.